BidaskClub Lowers Zynerba Pharmaceuticals (NASDAQ:ZYNE) to Buy

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday, May 29th, BidAskClub reports.

Several other brokerages have also recently commented on ZYNE. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 17th. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. Canaccord Genuity began coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, April 22nd. They issued a “buy” rating and a $8.09 price target for the company. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $26.00 price target on shares of Zynerba Pharmaceuticals in a research note on Monday, May 6th. Finally, HC Wainwright restated

... read more at: https://rocklandregister.com/2019/06/08/bidaskclub-lowers-zynerba-pharmaceuticals-zyne-to-buy.html